Searched for
SHARVIL PATEL
Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...- Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Indian Pharmaceutical Alliance appoints Zydus Lifesciences MD Sharvil Patel as new presidentThe Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel of Zydus Lifesciences as its new President, with Glenn Saldanha of Gle...
- IPA names Zydus Lifesciences MD Sharvil Patel as PresidentSharvil Patel is the new president of the Indian Pharmaceutical Alliance. He takes over from Samir Mehta. Glenn Saldanha becomes the vice p...
- Zydus inks licensing pact with Takeda to sell GERD drug"With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across ...
- Zydus bets big on proprietary drugs to boost revenueSharvil Patel, managing director of Zydus Lifesciences said, half of the research and development (R&D) allocation is geared towards develo...
- Zydus Lifesciences appoints Punit Patel as President & CEO, AmericasBefore joining Zydus, he was the President of Red Oak Sourcing, leading the company's "multibillion-dollar generic portfolio", overseeing a...
- Zydus buys rights from Pharmacosmos to sell drug to treat anemia in India, NepalMonoFerric injection is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron...
- Vaccine will soon be available for 12-18 age group: Cadila HealthcareThe government has allowed vaccination of adolescents aged 15 to 18 years with Bharat Biotech's Covaxin, but is yet to decide on vaccinatio...
- Cadila, Bayer extend JV partnership for three years"The spirit of partnership in this joint venture has all been about channelling the core strengths of both Zydus and Bayer for the benefit ...
- This year, Zydus to launch at least 40 generics in US markets: Sharvil PatelA large part of the future growth is being driven by innovation, says Zydus MD
- Sell Cadila Healthcare, target Rs 373: Dharmesh ShahSell Cadila Healthcare Ltd. at a price target of Rs 373.0 and a stop loss at Rs 402 from entry point.
- Buy Cadila Healthcare, target Rs 435: Manas JaiswalBuy Cadila Healthcare Ltd. at a price target of Rs 435.0 and a stop loss at Rs 419 from entry point.
- Biologics and vaccines businesses will be significant growth drivers post 2022: Sharvil Patel, CadilaWe have a healthy list of ANDAs that have been filed and coming up for approval.
- Sell Cadila Healthcare, target Rs 445: Manas JaiswalSell Cadila Healthcare at a price target of Rs 445 and a stop loss at Rs 470 from entry point.
- How billionaire father-son duo turned family firm into world beaterLast month Pankaj Patel announced his more than 20-years running the company were over.
- Cadila's new MD Sharvil Patel aims to double revenues in 5 yearsWith a doctoral degree from University of Sunderland, Sharvil is the third generation Patel to lead Cadila. The company was founded by his ...
- Pankaj Patel steps down as Cadila MD, son Sharvil to take overThe Board of Directors of Cadila Healthcare has unanimously approved the appointment of Sharvil P Patel as the Manging Director of the comp...
Load More
